morphine-3-glucuronide and naloxonazine

morphine-3-glucuronide has been researched along with naloxonazine* in 1 studies

Other Studies

1 other study(ies) available for morphine-3-glucuronide and naloxonazine

ArticleYear
Evidence for separate involvement of different mu-opioid receptor subtypes in itch and analgesia induced by supraspinal action of opioids.
    Journal of pharmacological sciences, 2008, Volume: 106, Issue:4

    The common adverse effect of centrally-injected mu-opioid receptor (mu-OR) agonists is pruritus. This study was conducted using mice to examine whether different subtypes of mu-OR would be responsible for pruritus and analgesia. Intracisternal injections of morphine and morphine-6beta-glucronide (M6G), but not M3G, produced an antinociceptive effect. Morphine, but neither M6G nor M3G, induced facial scratching, a pruritus-related response. Facial scratching following morphine was not affected by the mu(1)-OR antagonist naloxonazine at doses that inhibited the antinociceptive effects. The results suggest that different subtype and/or splice variants of mu-OR are separately involved in pruritus and antinociception of opioids.

    Topics: Analgesics, Opioid; Animals; Behavior, Animal; Dose-Response Relationship, Drug; Injections, Subcutaneous; Male; Mice; Mice, Inbred ICR; Morphine; Morphine Derivatives; Naloxone; Narcotic Antagonists; Pain Measurement; Pain Threshold; Pruritus; Receptors, Opioid, mu; Time Factors

2008